| findings indicate that other oncogenic mechanism(s) may be involved in the development of solid tumors in Emu-TCL1 transgenic mice | None |
| The TCL1 oncoprotein binds the RNase PH domains of the PNPase exoribonuclease without affecting its RNA degrading activity. | None |
| Biological action of the proto-oncogene TCL1 family and the development avenues for a suppressive drug specific for Akt, a core intracellular survival regulator.[REVIEW] | None |
| Proto-oncogene TCL1: more than just a coactivator for Akt. | None |
| TORC2 regulates germinal center repression of the TCL1 oncoprotein to promote B cell development and inhibit transformation. | None |
| The TCL1 oncoprotein inhibits activation-induced cell death by impairing PKCtheta and ERK pathways. | None |
| The Tcl1 oncogene defines secondary hair germ cells differentiation at catagen-telogen transition and affects stem-cell marker CD34 expression. | None |
| The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. | None |
| Characterization and localization of the TCL-1 oncogene product. | None |
| The murine Tcl1 oncogene: embryonic and lymphoid cell expression. | None |